Reference : Comment je traite ... la leucemie myeloide chronique (LMC).
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/9459
Comment je traite ... la leucemie myeloide chronique (LMC).
French
[en] How I treat...chronic myeloid leukemia
Hafraoui, Kaoutar mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Humblet-Baron, Stéphanie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Pédiatrie CHR >]
Baron, Frédéric mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Fillet, Georges mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
2003
Revue Médicale de Liège
58
1
7-12
Yes (verified by ORBi)
0370-629X
Belgium
[en] Algorithms ; Antimetabolites, Antineoplastic/therapeutic use ; Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Cytarabine/therapeutic use ; Enzyme Inhibitors/therapeutic use ; Fusion Proteins, bcr-abl/antagonists & inhibitors ; Hematopoietic Stem Cell Transplantation ; Humans ; Interferon-alpha/therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy ; Piperazines/therapeutic use ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Pyrimidines/therapeutic use
[en] This review article describes the identification of the tyrosine kinase BCR/ABL as the hallmark of chronic myeloid leukemias (CML) as well as the development of a specific inhibitor of this tyrosine kinase, the STI571 (Glivec, imatinib mesylate). The authors discuss the results of a phase I and three phase II trials reporting the efficacy of STI571 as treatment for CML patients and propose two simplified algorithms that may help to guide decision-making for the individual patient.
http://hdl.handle.net/2268/9459

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
185-Author.pdfNo commentaryPublisher postprint65.72 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.